In a call with investors after the results were announced, Martin Lange, executive vice president of R&D, chief scientific officer and member of the Management Board for Novo Nordisk, explained that Zepbound performed unusually well on efficacy compared to what has typically been reported in most previous trials of a similar nature. In a phase 3 trial in adults with pre-diabetes and obesity, participants had an average weight reduction of 22.9% on the highest dose of tirzepatide, 2.1% less weight loss than was seen in the CagriSema comparator trial
Alternatively, if the elevated anion gap persists despite cessation of acetaminophen and administration of N-acetylcysteine, pyroglutamic acidosis is unlikely, and an alternative diagnosis should be sought
520 Colorectal cancer The potential impact of GLP-1RAs on colorectal cancer (CRC) treatment is achieved through the modulation of Bone Morphogenetic Protein 4 (BMP4)
These results indicate that GLP-1RAs have protective effects against vascular calcification in Pi-treated VSMCs, and these effects could be mediated by inhibition of VSMCs transdifferentiation into osteoblast-like cells via amelioration of ER stress
Toprak, C